Evaluation of the efficacy of a bacteriophage in the treatment of pneumonia induced by multidrug resistance klebsiella pneumoniae in mice

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Cao, Fang ^a,b   Wang, Xitao ^a   Wang, Linhui ^a   Li, Zhen ^a   Che, Jian ^a   Wang, Lili ^a   Li, Xiaoyu ^a   Cao, Zhenhui ^a   Zhang, Jiancheng ^a   Jin, Liji ^a   Xu, Yongping ^a  

^a DALIAN UNIVERSITY OF TECHNOLOGY   (China)

^b DALIAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; ANTIINFECTIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL GROWTH; BACTERIAL LOAD; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIOPHAGE; BACTERIUM ISOLATE; BODY WEIGHT; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; IN VITRO STUDY; INOCULATION; KLEBSIELLA PNEUMONIAE; LATENT PERIOD; LUNG LESION; MOUSE; MULTIDRUG RESISTANCE; MULTIDRUG RESISTANT KLEBSIELLA PNEUMONIAE; NONHUMAN; NUCLEOTIDE SEQUENCE; PNEUMONIA; SIPHOVIRIDAE; ANIMAL; GENETICS; HUMAN; KLEBSIELLA INFECTIONS; PATHOGENICITY; VIROLOGY;

BACTERIA (MICROORGANISMS); KLEBSIELLA PNEUMONIAE; MUS; SIPHOVIRIDAE;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIOPHAGES; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MICE;

EID: 84927139007     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/752930     Document Type: Article

References (30)

1. H. Hackstein, S. Kranz, A. Lippitsch et al., "Modulation of respiratory dendritic cells during Klebsiella pneumonia infection", Respiratory Research, vol. 14, no. 1, article 91, 2013.
2. R. Podschun and U. Ullmann, "Klebsiella spp. as nosocomial pathogens: epidemiology, taxonomy, typing methods, and pathogenicity factors", Clinical Microbiology Reviews, vol. 11, no. 4, pp. 589-603, 1998.
3. S. J. Cryz, "Progress in immunization against Klebsiella infections", European Journal of Clinical Microbiology, vol. 2, no. 6, pp. 523-528, 1983.
4. J. M. Zhu, R. J. Jiang, H. S. Kong et al., "Emergence of novel variants of gyrA, parC, qnrS genes in multi-drug resistant Klebsiella caused pneumonia", Zhonghua Liu Xing Bing Xue Za Zhi, vol. 34, pp. 61-66, 2013.
5. D. K. Pomakova, C.-B. Hsiao, J. M. Beanan et al., "Clinical and phenotypic differences between classic and hypervirulent Klebsiella pneumonia: an emerging and under-recognized pathogenic variant", European Journal of Clinical Microbiology & Infectious Diseases, vol. 31, no. 6, pp. 981-989, 2012.
6. NDM-1", Diagnostic Microbiology and Infectious Disease, vol. 78, no. 1, pp. 93-97, 2014.
7. K. Demirdag and S. Hosoglu, "Epidemiology and risk factors for ESBL-producing Klebsiella pneumoniae: a case control study", Journal of Infection in Developing Countries, vol. 4, no. 11, pp. 717-722, 2010.
8. E. B. Hirsch and V. H. Tam, "Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection", Journal of Antimicrobial Chemotherapy, vol. 65, no. 6, pp. 1119-1125, 2010.
9. S. Chhibber, S. Kaur, and S. Kumari, "Therapeutic potential of bacteriophage in treating Klebsiella pneumoniae B5055-mediated lobar pneumonia in mice", Journal of Medical Microbiology, vol. 57, no. 12, pp. 1508-1513, 2008.
10. J. J. Hilliard, J. L. Melton, L. Hall et al., "Comparative effects of carbapenems on bacterial load and host immune response in a Klebsiella pneumoniaemurine pneumoniamodel", Antimicrobial Agents and Chemotherapy, vol. 55, no. 2, pp. 836-844, 2011.
11. F. Pouillot, M. Chomton, H. Blois et al., "Efficacy of bacteriophage therapy in experimental sepsis and meningitis caused by a clone O25b: H4-ST131 Escherichia coli strain producing CTXM-15", Antimicrobial Agents and Chemotherapy, vol. 56, no. 7, pp. 3568-3575, 2012.
12. B. Biswas, S. Adhya, P. Washart et al., "Bacteriophage therapy rescues mice bacteremic from a clinical isolate of vancomycinresistant Enterococcus faecium", Infection and Immunity, vol. 70, no. 1, pp. 204-210, 2002.
13. J. Gu, X. Liu, Y. Li et al., "Amethod for generation phage cocktail with great therapeutic potential", PLoS ONE, vol. 7, no. 3, Article ID e31698, 2012.
14. R. Capparelli, M. Parlato, G. Borriello, P. Salvatore, and D. Iannelli, "Experimental phage therapy against Staphylococcus aureus in mice", Antimicrobial Agents and Chemotherapy, vol. 51, no. 8, pp. 2765-2773, 2007.
15. E. Kutter, D. de Vos, G. Gvasalia et al., "Phage therapy in clinical practice: treatment of human infections", Current Pharmaceutical Biotechnology, vol. 11, no. 1, pp. 69-86, 2010.
16. H. Brüssow, "What is needed for phage therapy to become a reality in Western medicine?" Virology, vol. 434, no. 2, pp. 138-142, 2012.
17. B. K. Chan, S. T. Abedon, and C. Loc-Carrillo, "Phage cocktails and the future of phage therapy", Future Microbiology, vol. 8, no. 6, pp. 769-783, 2013.
18. E. L. Ellis and M. Delbruck, "The growth of bacteriophage", The Journal of General Physiology, vol. 22, pp. 365-384, 1939.
19. F. Okada, Y. Ando, K. Honda et al., "Acute Klebsiella pneumoniae pneumonia alone and with concurrent infection: comparison of clinical and thin-section CT findings", British Journal of Radiology, vol. 83, no. 994, pp. 854-860, 2010.
20. C. H. Lester, S. S. Olsen, L. Jakobsen et al., "Emergence of extended-spectrum β-lactamase (ESBL)-producing Klebsiella pneumoniae in Danish hospitals; This is in part explained by spread of two CTX-M-15 clones withmultilocus sequence types 15 and 16 in Zealand", International Journal of Antimicrobial Agents, vol. 38, no. 2, pp. 180-182, 2011.
21. A. Adler, E. Khabra, I. Chmelnitsky et al., "Development and validation of a multiplex PCR assay for identification of the epidemic ST-258/512 KPC-producing Klebsiella pneumoniae clone", Diagnostic Microbiology & Infectious Disease, vol. 78, no. 1, pp. 12-15, 2014.
22. S. Ambretti, P. Gaibani, F. Caroli, L. Miragliotta, and V. Sambri, "A carbapenem-resistant Klebsiella pneumoniae isolate harboring KPC-I from Italy", New Microbiologica, vol. 33, no. 3, pp. 281-282, 2010.
23. X. Wittebole, S. de Roock, and S. M. Opal, "Ahistorical overview of bacteriophage therapy as an alternative to antibiotics for the treatment of bacterial pathogens", Virulence, vol. 5, no. 1, pp. 226-235, 2014.
24. D. R. Harper and M. C. Enright, "Bacteriophages for the treatment of Pseudomonas aeruginosa infections", Journal of Applied Microbiology, vol. 111, no. 1, pp. 1-7, 2011.
25. M. Kim and S. Ryu, "Characterization of a T5-like coliphage, SPC35, and differential development of resistance to SPC35 in Salmonella enterica serovar typhimurium and Escherichia coli", Applied and Environmental Microbiology, vol. 77, no. 6, pp. 2042-2050, 2011.
26. M. Skurnik and E. Strauch, "Phage therapy: facts and fiction", International Journal of Medical Microbiology, vol. 296, no. 1, pp. 5-14, 2006.
27. S. Matsuzaki, M. Yasuda, H. Nishikawa et al., "Experimental protection ofmice against lethal Staphylococcus aureus infection by novel bacteriophage φMR11", Journal of Infectious Diseases, vol. 187, no. 4, pp. 613-624, 2003.
28. E. Morello, E. Saussereau, D. Maura, M. Huerre, L. Touqui, and L. Debarbieux, "Pulmonary bacteriophage therapy on Pseudomonas aeruginosa cystic fibrosis strains: First steps towards treatment and prevention", PLoS ONE, vol. 6, no. 2, Article ID e16963, 2011.
29. J. Bordon, S. Aliberti, R. Fernandez-Botran et al., "Understanding the roles of cytokines and neutrophil activity and neutrophil apoptosis in the protective versus deleterious inflammatory response in pneumonia", International Journal of Infectious Diseases, vol. 17, no. 2, pp. e76-e83, 2013.
30. M. Zimecki, J. Artym, M. Kociêba, B. Weber-Dąbrowska, J. Borysowski, and A. Gárski, "Effects of prophylactic administration of bacteriophages to immunosuppressed mice infected with Staphylococcus aureus", BMC Microbiology, vol. 9, article 169, 2009.